Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952  by Vujkovic, Marijana et al.
Leukemia Research Reports 4 (2015) 47–50Contents lists available at ScienceDirectLeukemia Research Reportshttp://d
2213-04
n Corr
Hospita
E-mjournal homepage: www.elsevier.com/locate/lrrAssociations between genetic variants in folate and drug metabolizing
pathways and relapse risk in pediatric acute lymphoid leukemia on
CCG-1952
Marijana Vujkovic a,n, Aaron Kershenbaumb, Lisa Wray c, Thomas McWilliams a,
Shannon Cannon d, Meenakshi Devidas e, Linda Stork e, Richard Aplenc a
a Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA
b University of Pennsylvania School of Medicine, Philadelphia, PA, USA
c Alfred I. duPont Hospital for Children, Wilmington, DE, USA
d University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
e Department of Biostatistics, Colleges of Medicine and Public Health and Health Professions, University of Florida, Gainesville, FL, USAa r t i c l e i n f o
Article history:
Received 17 April 2015
Received in revised form
19 May 2015
Accepted 27 May 2015
Available online 21 July 2015
Keywords:
Acute lymphoblastic leukemia
SNPs
Relapse
Folate pathwayx.doi.org/10.1016/j.lrr.2015.05.005
89/Published by Elsevier Ltd. This is an open
espondence to: 4200 Colket Translational R
l of Philadelphia, 3501 Civic Center Boulevard,
ail address: vujkovicm@email.chop.edu (M. Vua b s t r a c t
Genetic variation in drug detoxiﬁcation pathways may inﬂuence outcomes in pediatric acute lympho-
blastic leukemia (ALL). We evaluated relapse risk and 24 variants in 17 genes in 714 patients in CCG-1961.
Three TPMT and 1 MTR variant were associated with increased risks of relapse (rs4712327, OR 3.3, 95%CI
1.2–8.6; rs2842947, OR 2.7, 95%CI 1.1–6.8; rs2842935, OR 2.5, 95%CI 1.1–5.0; rs10925235, OR 4.9, 95%CI
1.1–25.1). One variant in SLC19A1 showed a protective effect (rs4819128, OR 0.5, 95%CI 0.3–0.9). Our
study provides data that relapse risk in pediatric ALL is associated with germline variations in TPMT,MTR
and SLC19A1.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The introduction of risk-adapted intensiﬁed combination ther-
apy has markedly improved outcomes for children with acute
lymphoblastic leukemia (ALL). Unfortunately, disease recurrence
and treatment-induced toxicity remain clinically relevant risks [1].
Candidate gene studies previously reported that polymorphisms in
genes encoding for enzymes in folate metabolism and drug de-
toxiﬁcation pathways (e.g. TPMT, MTHFR, CBS, MTR, and DHFR) may
modify relapse and treatment toxicity risk [2,3]. We sought to
evaluate single nucleotide polymorphism (SNPs) in these path-
ways to validate previous reports. We expanded our previous
candidate gene genotyping efforts to include 24 SNPs in 17 genes
(MTHFR, MTR, PTH1R, ABCG2, MTRR, TPMT, SOD2, ABCB1, GGH, EN-
OSF1, GSTP1, LRP5, NQO1, SHMT1, TYMS, SLC19A1, and CBS) in the
folate and drug metabolizing pathway for their association with
risk of relapse in 714 children who had been treated in the CCG-
1952 study [4]. Between 1996 and 2000, a total of 2027 pediatric
patients were enrolled in the CCG-1952 study. This studyaccess article under the CC BY-NC
esearch Building, Children's
Philadelphia, PA 19104, USA.
jkovic).compared the use of intrathecal (IT) methotrexate to IT triple (ITT)
chemotherapy (methotrexate, cytarabine, and hydrocortisone so-
dium succinate) and oral mercaptopurine to thioguanine in
treating children with standard-risk ALL. Guardians provided
written informed consent and permission for the use of archived
samples in accordance with National Institutes of Health
guidelines.
The primary outcome in the present study was ALL relapse,
deﬁned as an isolated or combined M3 (425% blasts) disease
recurrence event in the bone marrow and/or extramedullary sites
after achieving initial remission. Occasionally bone marrow re-
lapse was deﬁned as M2 (5–25% blasts) with conﬁrmation at re-
lapse of the diagnostic cytogenetic clone. Isolated central nervous
system relapse was deﬁned as Z5 white blood cells per microliter
in the cerebrospinal ﬂuid, with morphologically identiﬁable blasts
on cytospin. Germline DNA on 714 samples was collected at re-
mission and extracted from remission bone marrow aspirate
specimens using the Qiagen Puregene Core Kit A. Genotyping was
performed using either Pyrosequencing, Taqman Open Array
platforms, direct sequencing, or standard restriction fragment
length polymorphism. All SNPs were in Hardy–Weinberg equili-
brium with a minor allele frequency (AF) exceeding 10%.
Logistic and Cox regression models were used to evaluate the-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient characteristics of the overall and genotyped sub-cohort of the CCG-1952
study.
CCG-1952 Overall Genotyped P
Characteristics N % N %
n 2027 100.0 714 100.0
Age 1–1.99 165 8.1 62 8.7 0.78
2–5.99 1402 69.2 493 69.0
6–9.99 460 22.7 159 22.3
Sex Male 1129 55.7 375 52.5 0.03
Female 898 44.3 339 47.5
Race/Ethnicity White 1376 68.2 537 75.2 o0.01
Black 72 3.6 23 3.2
Hispanic 444 22.0 98 13.7
Other 125 6.2 56 7.8
Immunophenotype B-cell 1802 93.3 577 95.8 o0.01
T-cell 130 6.7 25 4.2
Relapse No 1693 83.5 602 84.3 0.47
Yes 334 16.5 112 15.7
Total summations of less than 2027 patients in the overall cohort, or less than 714
patients in the genotyped sub-cohort, are due to missing observations.
Table 2
Odds ratios and hazard ratios of SNPs on ALL relapse.
Gene Allele Size Relapse Remission
SNP rs# A B n BB/AB/AA BB/AB/AA
MTHFR
rs1801131 A C 637 3/49/47 62/219/257
rs1801133 C T 525 17/30/37 51/193/197
MTR
rs10925235 C T 417 4/32/34 49/160/138
rs1805087 A G 478 4/19/49 16/100/290
PTH1R
rs1138518 C T 305 5/22/15 36/120/107
ABCG2
rs2231142 G T 327 1/11/34 2/45/234
MTRR
rs1532268 C T 393 3/32/29 38/132/159
rs162036 A G 415 2/21/47 13/100/232
TPMT
rs2842947 C T 484 50/19/8 272/110/25
TPMT
rs4712327 G A 377 8/15/38 21/85/210
rs2842935 C T 487 43/23/12 225/145/39
SOD2
rs4880 A G 320 16/25/12 76/138/53
ABCB1
rs1045642 G A 339 7/25/15 68/151/73
GGH
rs11545078 G A 337 2/9/35 16/43/232
GSTP1
rs1695 A G 328 6/24/17 34/118/129
rs1138272 C T 320 1/16/25 1/101/176
LRP5
rs2306862 C T 345 4/14/28 7/74/218
NQO1
rs1800566 G A 331 3/9/32 22/102/163
SHMT1
rs2273026 C T 461 1/13/61 5/94/287
TYMS
rs2853533 C G 312 25/17/4 168/79/19
ENOSF1
rs3744962 A G 422 0/11/61 4/77/269
SLC19A1
rs4819128 C T 478 17/40/20 116/221/64
CBS
rs466791 C T 411 0/14/55 8/92/242
rs719038 A G 398 9/28/23 23/158/157
Single nucleotide polymorphisms (SNPs) are grouped by gene in relapsed and unaffected
(P). All estimates have been adjusted for the potential covarying factors of: age, race,
dominant homozygote.
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the effects of heterozygous (AB) and homozygous recessive (BB)
patients separately. In both cases the dominant homozygous (AA)
patients were chosen as the reference category. All risk estimates
were adjusted for age, race, gender and immunophenotype. The
difference in relapse rates among genotypes of signiﬁcantly asso-
ciated SNPs are visualized with Kaplan–Meier curves.2. Results
From the 2027 patients in the overall cohort, genotyping in-
formation was available on 714 patients. Female, white, and pa-
tients with B-cell lineage progenitor ALL were slightly more re-
presented in the genotyped samples (Table 1). There was no dif-
ference in the occurrence of relapse between genotyped and non-
genotyped patients (334/2027 [16.5%] versus 112/714 [15.3%]).
Genotype association results are presented in Table 2. A subset
of SNPs in the TPMT gene, speciﬁcally variants in rs4712327,
rs2842947, and rs2842935, were associated with increased risks of
relapse (OR 3.3, 95%CI 1.2–8.6; OR 2.7, 95%CI 1.1–6.8; OR 2.5, 95%CI
1.1–5.0, respectively). These three SNPs were in high linkageHeterozygote Homozygote Heterozygote Homozygote
OR (95%CI) OR (95%CI) HR (95%CI) HR (95%CI)
3.2 (0.9–11) 2.6 (0.8–8.9) 2.9 (0.99.4) 2.5 (0.88.2)
0.7 (0.4–1.2) 1.4 (0.6–3.0) 0.7 (0.41.2) 1.4 (0.72.7)
4.1 (0.9–18) 4.9 (1.1–22) 3.7 (0.915.7) 4.1 (1.017.4)
1.3 (0.7–2.4) 1.8 (0.6–5.9) 1.2 (0.72.1) 1.5 (0.54.4)
1.4 (0.4–4.6) 1.0 (0.3–3.5) 1.3 (0.43.9) 1 (0.33.2)
2.1 (0.9–4.9) 5.5 (0.5–68) 1.9 (0.94.1) 4.3 (0.632.2)
4.0 (0.9–18) 2.6 (0.6–12) 3.5 (0.8–15.0) 2.7 (0.611.4)
1.0 (0.5–1.9) 0.3 (0.0–2.6) 1.1 (0.61.9) 0.4 (0.12.8)
1.5 (0.8–2.8) 2.7 (1.1–6.8) 1.6 (0.92.8) 2.2 (1.04.8)
1.2 (0.6–2.4) 3.3 (1.2–8.6) 1.2 (0.62.4) 2.4 (1.15.3)
2.5 (1.0–5.0) 2.5 (1.1–5.0) 0.5 (0.2–1.0) 0.5 (0.20.9)
1.1 (0.5–2.5) 1.1 (0.4–2.8) 1 (0.5–2.2) 1 (0.4–2.4)
0.9 (0.4–2.1) 0.4 (0.1–1.3) 1 (0.5–1.9) 0.4 (0.2–1.2)
1.7 (0.7–4.1) 1.1 (0.2–5.1) 1.5 (0.7–3.3) 1 (0.2–4.3)
1.9 (0.9–4.1) 1.2 (0.4–3.9) 1.6 (0.8–3.3) 1.4 (0.5–3.9)
0.2 (0.0–3.6) 0.1 (0.0–2.3) 0.3 (0.0–2.6) 0.2 (0.0–1.6)
0.7 (0.1–4.4) 0.6 (0.1–3.5) 0.5 (0.1–2.3) 0.4 (0.1–1.8)
0.5 (0.2–1.1) 0.2 (0.0–1.8) 0.5 (0.2–1.2) 0.3 (0–2.1)
0.7 (0.3–1.4) 0.8 (0.1–7.1) 0.7 (0.3–1.3) 0.8 (0.1–5.9)
1.2 (0.3–5.2) 0.7 (0.2–2.8) 1.3 (0.4–4.4) 0.7 (0.2–2.5)
0.6 (0.3–1.4) na 0.7 (0.3–1.4) na
0.5 (0.3–0.9) 0.4 (0.2–1.0) 0.6 (0.3–1.0) 0.5 (0.3–1.0)
0.6 (0.3–1.2) na 0.6 (0.3–1.1) na
0.4 (0.1–1.2) 0.4 (0.1–1.1) 0.5 (0.2–1.1) 0.4 (0.2–1.0)
patients, together with odds ratios (OR), 95% conﬁdence intervals (CI) and p-values
gender, and immunophenotype. BB, recessive homozygote; AB, heterozygote; AA,
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Fig. 1. Relapse-free survival of selected SNPs in pediatric ALL. Kaplan–Meier curves for relapse-free survival stratiﬁed by SNP genotype, e.g. dominant homozygote (AA),
heterozygote (AB) and recessive homozygote (BB).
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ditionally, one SNP in the MTR gene, rs10925235, was associated
with relapse (OR 4.9, 95%CI 1.1–25.1) (Fig. 1). SLC19A1 variant
rs4819128 showed a signiﬁcant protective effect on relapse both in
heterozygote (OR 0.5, 95%CI 0.3–0.9) and recessive homozygote
(OR 0.4, 95%CI 0.2–1.0) patients. Borderline signiﬁcant protective
effects were observed for two SNPs upstream of CBS: rs466791 (OR
0.6, 95%CI 0.3–1.2) and rs719038 (OR 0.4, 95%CI 0.1–1.2). A bor-
derline signiﬁcant association between the MTHFR C677T poly-
morphism and relapse-free survival was observed; both hetero-
zygote and homozygote patients showed a 42.5 fold increased
risk for relapse.3. Discussion
Our results conﬁrm that germline variations in the TPMT gene
are associated with treatment outcome in children with ALL [5].
The ability of TPMT to catalyze S-methylation and inactivate
6-mercaptopurine makes it a major determinant of 6-mercapto-
purine toxicity. Furthermore, reduced TPMT activity is associated
with both methotrexate availability and occurrence of minimal
residual disease after induction chemotherapy [6]. While these
intronic SNPs may have an unknown regulatory function, it is
more likely that the observed effects of intronic SNPs are due to a
nearby exonic TPMT variant. All three intronic SNPs are in close LD
with the TPMT*2 variant (min. D′¼0.67).
The MTHFR gene modulates methotrexate toxicity and is an-
other well-investigated example of pharmacogenetics in pediatric
ALL treatment-related outcome [3,7,8]. The observed borderline
statistical signiﬁcance may be a sample size issue as our study
contains merely 3 relapse patients with the MTHFR 677TT
genotype.
Previously Sepe et al. observed a signiﬁcant association be-
tween the MTRR G66A (rs1801394) variant allele and relapse risk
among 557 patients in the predecessor COG study, CCG-1891 [3].Another study reported a relationship between the MTRR G66A
variant and in vitro methotrexate sensitivity among 119 patients
but did not investigate treatment outcome [9]. In the current
study, the MTRR variant rs1532268 was borderline associated with
relapse risk and is in moderate LD with MTRR G66A (D′¼0.37),
whereas rs162036 which is in high LD with MTRR G66A (D′¼1.00)
was not associated with relapse. Since the recessive homozygous
variant ofMTR G66A was not observed in our study, we believe we
are underpowered to detect associations in this SNP.
In our data, an intronic MTR variant (rs10925235) was highly
associated with ALL treatment outcome whereas the known mis-
sense mutation in MTR A2756G (rs1805087) was not. The two
SNPs are in perfect LD and point towards the same direction of
association, however the intronic variant has a higher allele fre-
quency than the exonic variant (AF¼0.35 in rs10925235, AF¼0.21
in rs1805087). The gain in statistical power from the higher allele
frequency may explain why signiﬁcance was reached by this in-
tronic variant and not in the missense MTR A2756G mutation.
Our ﬁnding that multiple SNPs upstream of CBS (rs719038,
rs466791) may be associated with the response to anti-leukemic
therapy in childhood ALL has not been previously reported. Within
CBS, two consecutive SNPs showed a consistent trend towards a
protective effect for relapse, although the trend was not statisti-
cally signiﬁcant.
Previous studies show varied results on the role of GSPT1 in ALL
treatment response, ranging from a protective [2,10] to a risk as-
sociation between the GSTP1 Val105/Val105 (rs1695) genotype and
relapse [3]. Our data suggest an increased risk, although not sta-
tistically signiﬁcant (OR for heterozygotes of 1.9, 95%CI 0.9–4.1)
and indicate that GSTP1 variants might have a modest effect on the
modiﬁcation of relapse risk.
Various observational studies have highlighted the importance
of the folate pathway in chemotherapeutic drug response, but the
speciﬁc results across these studies have been inconsistent [1]. The
current study provides additional data to support the hypothesis
that the risk of relapse after pediatric ALL treatment is associated
M. Vujkovic et al. / Leukemia Research Reports 4 (2015) 47–5050with germline variation in genes (e.g. TPMT, MTHFR and MTR) that
encode for enzymes that metabolize chemotherapeutic agents.
Additional work is needed to reﬁne these ﬁndings and to de-
termine which germline variants beyond TPMT have pharmaco-
genomic potential for pediatric ALL treatment.Conﬂict of interest statement
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